Siemens Healthineers AG Stock: price and insider trades · Germany
No insider purchase over the last 90 days. The latest, by Caron, Darleen, was filed 30 Mar 2026.
Siemens Healthineers AG: what insiders have been doing
Every trade that managers of Siemens Healthineers AG disclose to BaFin is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Erlangen, Germany. It was founded in 2017. From 9 November 2025 to 9 November 2026, the disclosure feed for Siemens Healthineers AG logged 15 filings by 6 insiders.
Every open-market trade in the period is a purchase: 4 purchases worth €427k, from 3 insiders, and not a single sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €200k from Staudinger-Leibrecht, Elisabeth, disclosed on 1 December 2025. The buyers include 2 senior executives and 1 board member.
With 15 filings in twelve months, the company is more active than the median of 5 filings across the 287 companies we follow on the same exchange. Over the whole record (from 2025), the tally stands at 5 purchases and no sales.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 30 March 2026, 223 days ago. Typically, a trade is published a median of 5 days after it takes place. Under the Market Abuse Regulation, managers have three business days to notify their trades.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by BaFin. They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- +13.9%Entry €36.39 · Close 16 Oct 2026 €41.45
- +12.7%Entry €36.78 · Close 16 Oct 2026 €41.45
- -2.1%Entry €42.33 · Close 16 Oct 2026 €41.45
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Siemens Healthineers AG Buy (bullish), based on 19 analysts. Average price target: €45.52.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2024FY ended September 2024 · cache
- 5,366.554 shares@ €36.960.0005% mcap100.0% of flowShareXETRAISIN DE000SHL1006BAFIN:40026744-e33058f6d995Canonical exit: 23 Jun 2026 (T+90)
- 500 shares@ €37.950.0001% mcap65.4% of flowShareING DirekthandelISIN DE000SHL1006BAFIN:40026744-aba7813f8f50Canonical exit: 16 Jun 2026 (T+90)
- ShareISIN DE000SHL1006BAFIN:40026744-db238dc9193a
- 250 shares@ €40.2034.6% of flowShareING DirekthandelISIN DE000SHL1006BAFIN:40026744-7b54efb248baCanonical exit: 12 May 2026 (T+90)
- 4,656.56 shares@ €42.96100.0% of flowShareXETRAISIN DE000SHL1006BAFIN:40026744-23867959ddb7Canonical exit: 25 Feb 2026 (T+90)
- ShareISIN DE000SHL1006BAFIN:40026744-d7cae707d1bd
- ShareISIN DE000SHL1006BAFIN:40026744-a958bd871f1b
- ShareISIN DE000SHL1006BAFIN:40026744-7c8f77bbdbc1
- ShareISIN DE000SHL1006BAFIN:40026744-731bca46f1a1
- ShareISIN DE000SHL1006BAFIN:40026744-29539b5d2ea4
- ShareISIN DE000SHL1006BAFIN:40026744-16eaee9ed15e
- ShareISIN DE000SHL1006BAFIN:40026744-2fe6a9d67b08
- ShareISIN DE000SHL1006BAFIN:40026744-239dfc3fdb71
- ShareISIN DE000SHL1006BAFIN:40026744-2e6dc9870921
- ShareISIN DE000SHL1006BAFIN:40026744-4bf367d45399
- 2,256 shares@ €46.53100.0% of flowShareING DirekthandelISIN DE000SHL1006BAFIN:40026744-fc65d1129657Canonical exit: 30 Oct 2025 (T+90)
- ShareISIN DE000SHL1006BAFIN:40026744-a4a9fa59b9e1
- ShareISIN DE000SHL1006BAFIN:40026744-a4a9fa59b9e1-2
- ShareISIN DE000SHL1006BAFIN:40026744
19 of 19 declarations
About Siemens Healthineers AG
Siemens Healthineers AG is a global medical technology group listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany under the ticker SHL.DE. The company supplies healthcare technologies to hospitals, laboratories and care providers, making it a capital-intensive medtech franchise with exposure to healthcare investment cycles. Its headquarters are in Erlangen, Bavaria, within Siemens’ historic industrial ecosystem. Siemens Healthineers emphasizes more than 125 years of heritage in healthcare technology, while its current corporate structure was established with the spin-off and IPO completed in 2018. ([siemens-healthineers.com](https://www.siemens-healthineers.com/press/features/pf-hq-opening?utm_source=openai))
The business is organized around three major strategic pillars. Imaging covers diagnostic and interventional imaging, including MRI, CT, ultrasound, X-ray and angiography platforms. Diagnostics includes laboratory diagnostics, molecular medicine, point-of-care testing and related services. The group has also expanded its treatment exposure through Varian and Advanced Therapies, which are now central to its therapy strategy. This structure allows Siemens Healthineers to address the full care continuum, from detection to treatment, while increasingly embedding artificial intelligence and digital workflows across the portfolio. ([siemens-healthineers.com](https://www.siemens-healthineers.com/press/releases/cmd2025?utm_source=openai))
Read moreShow less
In competitive terms, Siemens Healthineers is one of the leading players in medical imaging globally and holds strong positions in several premium categories, particularly interventional imaging, CT and integrated cancer care. Its competitive advantage rests on a large installed base, long-term customer relationships with healthcare systems, recurring service revenue and a sustained innovation pipeline. The company also highlights strengths in digital, data and AI, as well as digital patient twins and precision therapy. Geographically, it has a broad global footprint spanning Europe, North America and Asia-Pacific, with a particularly significant presence in the United States. ([siemens-healthineers.com](https://www.siemens-healthineers.com/de/about?utm_source=openai))
Recent developments point to solid operational execution. For fiscal 2025, ended September 30, 2025, Siemens Healthineers reported comparable revenue growth of 5.9%, adjusted EBIT of nearly €3.9 billion, an adjusted EBIT margin of 16.5%, and free cash flow of around €2.7 billion. In November 2025, the group also unveiled its new strategic phase, “Elevating Health Globally,” reorganizing financial reporting around Imaging, Precision Therapy and Diagnostics, while placing greater emphasis on AI and clinical partnerships. In early 2026, Siemens Healthineers continued to announce product launches and portfolio extensions in interventional imaging and oncology-related applications, underscoring an active innovation pipeline. ([siemens-healthineers.com](https://www.siemens-healthineers.com/press/releases/2025q4?utm_source=openai))
